EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity

Xu Han, Elizabeth A Knauss, Maria de la Fuente, Wei Li, Ronald A Conlon, David F LePage, Weihong Jiang, Stephanie A Renna, Steven E McKenzie, Marvin T Nieman

Journal of Thrombosis and Haemostasis · 2024-06 · 22 (6) · 1715-1726

DOI: 10.1016/j.jtha.2024.03.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-06. Verfasst von Xu Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University School of Medicine, Department of Pharmacology, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Blood Platelets, Receptors, Thrombin, Thrombin, Platelet Aggregation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Protease-activated receptor 4 (PAR4) mediates thrombin signaling on platelets and other cells. Our recent structural studies demonstrated that a single nucleotide polymorphism in extracellular loop 3 and PAR4-P310L (rs2227376) leads to a hyporeactive receptor. OBJECTIVES: The goal of this study was to determine how the hyporeactive PAR4 variant in extracellular loop 3 impacts platelet function in vivo using a novel knock-in mouse model (PAR4-322L). METHODS: A point mutation was introduced into the PAR4 gene F2rl3 via CRISPR/Cas9 to create PAR4-P322L, the mouse homolog to human PAR4-P310L. Platelet response to PAR4 activation peptide (AYPGKF), thrombin, ADP, and convulxin was monitored by αIIbβ3 integrin activation and P-selectin translocation using flow cytometry or platelet aggregation. In vivo responses were determined by the tail bleeding assay and the ferric chloride-induced carotid artery injury model. RESULTS: PAR4-P/L and PAR4-L/L platelets had a reduced response to AYPGKF and thrombin measured by P-selectin translocation or αIIbβ3 activation. The response to ADP and convulxin was unchanged among genotypes. In addition, both PAR4-P/L and PAR4-L/L platelets showed a reduced response to thrombin in aggregation studies. There was an increase in the tail bleeding time for PAR4-L/L mice. The PAR4-P/L and PAR4-L/L mice both showed an extended time to arterial thrombosis. CONCLUSION: PAR4-322L significantly reduced platelet responsiveness to AYPGKF and thrombin, which is in agreement with our previous structural and cell signaling studies. In addition, PAR4-322L had prolonged arterial thrombosis time. Our mouse model provides a foundation to further evaluate the role of PAR4 in other pathophysiological contexts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood PlateletsReceptors, ThrombinThrombinPlatelet AggregationPlatelet Glycoprotein GPIIb-IIIa ComplexMice, Inbred C57BLAnimalsDisease Models, AnimalCrotalid VenomsAdenosine DiphosphateP-SelectinPoint MutationGene Knock-In TechniquesSignal TransductionThrombosisMaleChloridesMicePlatelet ActivationCRISPR-Cas SystemsHumansPhenotypeFerric CompoundsOligopeptidesLectins, C-TypeReceptors, Proteinase-Activated

Stichwörter der Autor:innen

animal modelblood plateletsprotease-activated receptor 4single nucleotide polymorphismsthrombin receptor

Substanzen

Receptors, ThrombinThrombinPlatelet Glycoprotein GPIIb-IIIa Complexalanyl-tyrosyl-prolyl-glycyl-lysyl-phenylalanineprotease-activated receptor 4, mouseconvulxinprotease-activated receptor 4Crotalid VenomsAdenosine DiphosphateP-Selectin

Autor:innen und Institutionen

  • Case Western Reserve University School of Medicine, Department of Pharmacology, Cleveland, Ohio, USA.
  • Department of Biomedical Sciences, Joan C. Edwards School of Medicine at Marshall University, Huntington, West Virginia, USA.
  • Case Transgenic and Targeting Facility, Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Medicine, The Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Case Western Reserve University School of Medicine, Department of Pharmacology, Cleveland, Ohio, USA. Electronic address: marvin.nieman@case.edu.

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • American Heart Association
  • Center for AIDS Research, University of Washington
  • NIA
  • National Institutes of Health
  • NHLBI

Zitieren

APA

Han, X., Knauss, E. A., Fuente, M., Li, W., Conlon, R. A., LePage, D. F., Jiang, W., Renna, S. A., McKenzie, S. E., & Nieman, M. T. (2024). A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity. Journal of Thrombosis and Haemostasis, 22(6), 1715-1726. https://doi.org/10.1016/j.jtha.2024.03.004

Vancouver

Han X, Knauss EA, Fuente M, Li W, Conlon RA, LePage DF, et al. A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity. Journal of Thrombosis and Haemostasis. 2024;22(6):1715-1726. doi:10.1016/j.jtha.2024.03.004

BibTeX
@article{Han2024,
  author = {Han, Xu and Knauss, Elizabeth A and Fuente, Maria de la and Li, Wei and Conlon, Ronald A and LePage, David F and Jiang, Weihong and Renna, Stephanie A and McKenzie, Steven E and Nieman, Marvin T},
  title = {A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  volume = {22},
  number = {6},
  pages = {1715--1726},
  doi = {10.1016/j.jtha.2024.03.004}
}
Kostenlos starten →